vs
Side-by-side financial comparison of Amphastar Pharmaceuticals, Inc. (AMPH) and Getty Images Holdings, Inc. (GETY). Click either name above to swap in a different company.
Getty Images Holdings, Inc. is the larger business by last-quarter revenue ($282.3M vs $183.1M, roughly 1.5× Amphastar Pharmaceuticals, Inc.). Amphastar Pharmaceuticals, Inc. runs the higher net margin — 13.3% vs -32.2%, a 45.5% gap on every dollar of revenue. On growth, Getty Images Holdings, Inc. posted the faster year-over-year revenue change (14.1% vs -1.8%). Amphastar Pharmaceuticals, Inc. produced more free cash flow last quarter ($24.6M vs $7.7M). Over the past eight quarters, Getty Images Holdings, Inc.'s revenue compounded faster (12.7% CAGR vs 3.2%).
Amphastar Pharmaceuticals is a publicly traded American speciality pharmaceutical company. It was incorporated in May 2004 and primarily develops, manufactures, and sells inhalation and intranasal products.
Getty Images Holdings, Inc. is a visual media company and supplier of stock images, editorial photography, video, and music for businesses and consumers, with a library of over 477 million assets. It targets three markets—creative professionals, the media, and corporate.
AMPH vs GETY — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $183.1M | $282.3M |
| Net Profit | $24.4M | $-90.9M |
| Gross Margin | 46.8% | 74.8% |
| Operating Margin | 19.4% | -8.5% |
| Net Margin | 13.3% | -32.2% |
| Revenue YoY | -1.8% | 14.1% |
| Net Profit YoY | -35.7% | -467.6% |
| EPS (diluted) | $0.51 | $-0.22 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $183.1M | $282.3M | ||
| Q3 25 | $191.8M | $240.0M | ||
| Q2 25 | $174.4M | $234.9M | ||
| Q1 25 | $170.5M | $224.1M | ||
| Q4 24 | $186.5M | $247.3M | ||
| Q3 24 | $191.2M | $240.5M | ||
| Q2 24 | $182.4M | $229.1M | ||
| Q1 24 | $171.8M | $222.3M |
| Q4 25 | $24.4M | $-90.9M | ||
| Q3 25 | $17.4M | $21.6M | ||
| Q2 25 | $31.0M | $-34.4M | ||
| Q1 25 | $25.3M | $-102.6M | ||
| Q4 24 | $38.0M | $24.7M | ||
| Q3 24 | $40.4M | $-2.5M | ||
| Q2 24 | $37.9M | $3.7M | ||
| Q1 24 | $43.2M | $13.6M |
| Q4 25 | 46.8% | 74.8% | ||
| Q3 25 | 51.4% | 73.2% | ||
| Q2 25 | 49.6% | 72.1% | ||
| Q1 25 | 50.0% | 73.1% | ||
| Q4 24 | 46.5% | 73.5% | ||
| Q3 24 | 53.3% | 73.4% | ||
| Q2 24 | 52.2% | 72.5% | ||
| Q1 24 | 52.4% | 72.9% |
| Q4 25 | 19.4% | -8.5% | ||
| Q3 25 | 13.2% | 18.8% | ||
| Q2 25 | 24.2% | 15.1% | ||
| Q1 25 | 21.9% | 12.2% | ||
| Q4 24 | 24.2% | 14.5% | ||
| Q3 24 | 29.8% | 23.9% | ||
| Q2 24 | 30.3% | 20.3% | ||
| Q1 24 | 27.9% | 18.5% |
| Q4 25 | 13.3% | -32.2% | ||
| Q3 25 | 9.0% | 9.0% | ||
| Q2 25 | 17.8% | -14.6% | ||
| Q1 25 | 14.8% | -45.8% | ||
| Q4 24 | 20.4% | 10.0% | ||
| Q3 24 | 21.1% | -1.1% | ||
| Q2 24 | 20.8% | 1.6% | ||
| Q1 24 | 25.1% | 6.1% |
| Q4 25 | $0.51 | $-0.22 | ||
| Q3 25 | $0.37 | $0.05 | ||
| Q2 25 | $0.64 | $-0.08 | ||
| Q1 25 | $0.51 | $-0.25 | ||
| Q4 24 | $0.74 | $0.07 | ||
| Q3 24 | $0.78 | $-0.01 | ||
| Q2 24 | $0.73 | $0.01 | ||
| Q1 24 | $0.81 | $0.03 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $282.8M | $90.2M |
| Total DebtLower is stronger | $608.7M | $1.3B |
| Stockholders' EquityBook value | $788.8M | $552.5M |
| Total Assets | $1.6B | $3.2B |
| Debt / EquityLower = less leverage | 0.77× | 2.30× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $282.8M | $90.2M | ||
| Q3 25 | $276.2M | $109.5M | ||
| Q2 25 | $231.8M | $110.3M | ||
| Q1 25 | $236.9M | $114.6M | ||
| Q4 24 | $221.6M | $121.2M | ||
| Q3 24 | $250.5M | $109.9M | ||
| Q2 24 | $217.8M | $121.7M | ||
| Q1 24 | $289.6M | $134.2M |
| Q4 25 | $608.7M | $1.3B | ||
| Q3 25 | $608.6M | $1.3B | ||
| Q2 25 | $607.7M | $1.3B | ||
| Q1 25 | $603.9M | $1.3B | ||
| Q4 24 | $601.6M | $1.3B | ||
| Q3 24 | $596.4M | $1.3B | ||
| Q2 24 | $586.9M | $1.3B | ||
| Q1 24 | $594.0M | $1.4B |
| Q4 25 | $788.8M | $552.5M | ||
| Q3 25 | $776.7M | $634.6M | ||
| Q2 25 | $757.5M | $611.2M | ||
| Q1 25 | $751.3M | $593.0M | ||
| Q4 24 | $732.3M | $670.2M | ||
| Q3 24 | $727.7M | $683.4M | ||
| Q2 24 | $713.3M | $654.0M | ||
| Q1 24 | $672.4M | $640.8M |
| Q4 25 | $1.6B | $3.2B | ||
| Q3 25 | $1.7B | $2.6B | ||
| Q2 25 | $1.6B | $2.6B | ||
| Q1 25 | $1.6B | $2.6B | ||
| Q4 24 | $1.6B | $2.6B | ||
| Q3 24 | $1.5B | $2.6B | ||
| Q2 24 | $1.5B | $2.6B | ||
| Q1 24 | $1.6B | $2.6B |
| Q4 25 | 0.77× | 2.30× | ||
| Q3 25 | 0.78× | 2.11× | ||
| Q2 25 | 0.80× | 2.19× | ||
| Q1 25 | 0.80× | 2.21× | ||
| Q4 24 | 0.82× | 1.96× | ||
| Q3 24 | 0.82× | 1.97× | ||
| Q2 24 | 0.82× | 2.06× | ||
| Q1 24 | 0.88× | 2.16× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $32.9M | $20.6M |
| Free Cash FlowOCF − Capex | $24.6M | $7.7M |
| FCF MarginFCF / Revenue | 13.4% | 2.7% |
| Capex IntensityCapex / Revenue | 4.5% | 4.6% |
| Cash ConversionOCF / Net Profit | 1.35× | — |
| TTM Free Cash FlowTrailing 4 quarters | $121.2M | $5.7M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $32.9M | $20.6M | ||
| Q3 25 | $52.6M | $22.6M | ||
| Q2 25 | $35.6M | $6.5M | ||
| Q1 25 | $35.1M | $15.4M | ||
| Q4 24 | $29.0M | $39.7M | ||
| Q3 24 | $60.0M | $10.7M | ||
| Q2 24 | $69.1M | $46.4M | ||
| Q1 24 | $55.3M | $21.5M |
| Q4 25 | $24.6M | $7.7M | ||
| Q3 25 | $47.2M | $7.9M | ||
| Q2 25 | $25.0M | $-9.6M | ||
| Q1 25 | $24.4M | $-322.0K | ||
| Q4 24 | $16.6M | $24.6M | ||
| Q3 24 | $46.2M | $-1.8M | ||
| Q2 24 | $63.1M | $31.1M | ||
| Q1 24 | $46.5M | $7.1M |
| Q4 25 | 13.4% | 2.7% | ||
| Q3 25 | 24.6% | 3.3% | ||
| Q2 25 | 14.3% | -4.1% | ||
| Q1 25 | 14.3% | -0.1% | ||
| Q4 24 | 8.9% | 9.9% | ||
| Q3 24 | 24.1% | -0.8% | ||
| Q2 24 | 34.6% | 13.6% | ||
| Q1 24 | 27.1% | 3.2% |
| Q4 25 | 4.5% | 4.6% | ||
| Q3 25 | 2.8% | 6.1% | ||
| Q2 25 | 6.1% | 6.9% | ||
| Q1 25 | 6.3% | 7.0% | ||
| Q4 24 | 6.7% | 6.1% | ||
| Q3 24 | 7.2% | 5.2% | ||
| Q2 24 | 3.3% | 6.7% | ||
| Q1 24 | 5.1% | 6.5% |
| Q4 25 | 1.35× | — | ||
| Q3 25 | 3.03× | 1.05× | ||
| Q2 25 | 1.15× | — | ||
| Q1 25 | 1.39× | — | ||
| Q4 24 | 0.76× | 1.61× | ||
| Q3 24 | 1.48× | — | ||
| Q2 24 | 1.82× | 12.59× | ||
| Q1 24 | 1.28× | 1.58× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AMPH
| Other Products | $62.4M | 34% |
| Baqsimi | $46.7M | 26% |
| Primatenemist | $27.9M | 15% |
| Epinephrine | $17.1M | 9% |
| Lidocaine | $14.9M | 8% |
| Glucagon | $14.1M | 8% |
GETY
| Creative | $149.0M | 53% |
| Editorial | $109.4M | 39% |
| Other | $23.9M | 8% |
